Literature DB >> 2297858

Mildly dilated congestive cardiomyopathy. Use of prospective diagnostic criteria and description of the clinical course without heart transplantation.

A Keren1, S Gottlieb, D Tzivoni, S Stern, R Yarom, M E Billingham, R L Popp.   

Abstract

Prognosis in classically described dilated congestive cardiomyopathy has been reported to be related to ventricular size. Mildly dilated congestive cardiomyopathy (MDCM) has been defined as end-stage heart failure of unknown etiology (New York Heart Association class IV, left ventricular ejection fraction less than 30%), occurring with neither typical hemodynamic signs of restrictive myopathy nor significant ventricular dilatation (less than 15% above normal range). The present study includes follow-up in 12 nontransplant patients. In the first 4 months after diagnosis, two patients improved and are living, and two showed cardiac dilation and clinical deterioration and died. Six of the remaining eight with persistent MDCM died (four with intractable heart failure and two, sudden deaths) without change in ventricular size before death, despite medical therapy over 20 +/- 8 months. Eight comparable transplanted patients with persistent MDCM demonstrated improved total survival by life table analysis (p less than 0.05). A family history of congestive cardiomyopathy was found in nine of 16 patients (56%) with persistent MDCM. Nontransplant patients were older (p less than 0.02), but other findings were similar in the two groups. Endomyocardial biopsies available in 14 of 16 cases showed little or no myofibrillar loss in spite of severe hemodynamic impairment. The degree of myofibrillar loss did not correlate with hemodynamic parameters but showed good correlation with left ventricular size, that is, five of six patients with no myofibrillar loss had normal ventricular size, whereas all eight patients with mild myofibrillar loss had mild cardiomegaly (p less than 0.002). Our current experience suggests a somewhat variable but negative prognosis after prospective diagnosis of MDCM, with poor survival in patients with persistence of the original diagnostic features during follow-up. Preservation of heart size in MDCM is probably related to lack of significant myofibrillar loss. Thus, irrespective of heart size or myofibrillar preservation on biopsy, heart transplantation should be strongly considered in MDCM if signs of severe cardiac dysfunction persist despite therapy.

Entities:  

Mesh:

Year:  1990        PMID: 2297858     DOI: 10.1161/01.cir.81.2.506

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Predicting prognosis based on the shape of the left ventricular cavity in dilated cardiomyopathy: analysis using rate of improvement in the circle index.

Authors:  Yuichi Hirano; Hiroyuki Kayano; Tomoaki Kawamata; Tsutomu Toshida; Hiroaki Ueda; Hiromi Ando; Masaki Ozawa; Takashi Katagiri; Keisuke Abe
Journal:  J Med Ultrason (2001)       Date:  2006-12-22       Impact factor: 1.314

2.  Anthracycline-induced cardiomyopathy.

Authors:  N G Fisher; A J Marshall
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

Review 3.  Familial dilated cardiomyopathy.

Authors:  L Mestroni; M Krajinovic; G M Severini; B Pinamonti; A Di Lenarda; M Giacca; A Falaschi; F Camerini
Journal:  Br Heart J       Date:  1994-12

Review 4.  How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?

Authors:  J G Cleland; S Puri
Journal:  Br Heart J       Date:  1994-09

5.  Changes in myocardial cytoskeletal intermediate filaments and myocyte contractile dysfunction in dilated cardiomyopathy: an in vivo study in humans.

Authors:  S Di Somma; M Marotta; G Salvatore; G Cudemo; G Cuda; F De Vivo; M P Di Benedetto; F Ciaramella; G Caputo; O de Divitiis
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

6.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Back Sternick Eduardo; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong-Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti Mac Intyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Pablo Ochoa Juan; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  J Arrhythm       Date:  2022-05-31

7.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Eduardo Back Sternick; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti MacIntyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Juan Pablo Ochoa; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  Europace       Date:  2022-09-01       Impact factor: 5.486

8.  Speckle tracking echocardiography in hypokinetic non-dilated cardiomyopathy: comparison with dilated cardiomyopathy.

Authors:  Hoda Mombeini; Mozhgan Parsaee; Ahmad Amin
Journal:  ESC Heart Fail       Date:  2020-05-19

Review 9.  Multi-Modality Imaging in Dilated Cardiomyopathy: With a Focus on the Role of Cardiac Magnetic Resonance.

Authors:  Panagiota Mitropoulou; Georgios Georgiopoulos; Stefano Figliozzi; Dimitrios Klettas; Flavia Nicoli; Pier Giorgio Masci
Journal:  Front Cardiovasc Med       Date:  2020-07-02

10.  Outcome and prognostic value of N-terminal pro-brain natriuretic peptide and high-sensitivity C-reactive protein in mildly dilated cardiomyopathy vs. dilated cardiomyopathy.

Authors:  Jiayu Feng; Pengchao Tian; Lin Liang; Yuyi Chen; Yunhong Wang; Mei Zhai; Yan Huang; Qiong Zhou; Xuemei Zhao; Lang Zhao; Boping Huang; Liyan Huang; Yuhui Zhang; Jian Zhang
Journal:  ESC Heart Fail       Date:  2022-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.